

CASE STUDY

Bantry General Hospital, Ireland

 **71**

- # PARTICIPANTS** in retrospective audit of all Dexcom G6 rtCGM users¹ signed up to Clarity
- 87% type 1 diabetes, 13% type 2
 - Mean age 48 years
 - 58% male, 42% female



RETROSPECTIVE AUDIT

- All participants transitioned from self-monitoring of blood glucose (SMBG)
- Average sensor **compliance 94.5%**



AUDIT DURATION


- Audited data two years pre-intervention and up to one year following transition

OUTCOMES

Clear role for Dexcom rtCGM in the management of diabetes both from a clinical and health economics perspective.



HbA1c



-5 MMOL/MOL REDUCTION

Mean HbA1c reduced from **67 mmol/mol (8.28%)** to **62 mmol/mol (7.82%, p=0.07)**

-13 MMOL/MOL REDUCTION

in high baseline HbA1c group

Sub cohort with baseline HbA1c > 67 mmol/mol (8.28%, n=27) reported **average HbA1c reduction of 13 mmol/mol (p=0.0004)**



DIABETES SERVICE APPOINTMENTS OPPORTUNITY COST IMPACT



40 HOURS GAINED

due to reduction in service appointments following transition to rtCGM

48% REDUCTION

in diabetic service appointments with Dexcom rtCGM



DIABETES-RELATED HOSPITAL STATISTICS

81% REDUCTION

in diabetes-related admissions (p=0.1164) with Dexcom rtCGM

50% REDUCTION

in diabetes-related hospital bed days (p=0.1942) with Dexcom rtCGM

ESTIMATED COST-OFFSET OF €42,888 IN HOSPITAL ADMISSIONS AND BED DAYS¹

In terms of hospital admissions/bed days admissions

IMPROVING ACCESS TO LIFE-CHANGING TECHNOLOGY

"Given the improvement in HbA1c with use of the rtCGM amongst those with the worst baseline glycaemic control, there is clearly an argument for expansion of the availability of this technology to improve clinical outcomes."

Maher LC, O'Donovan MC, and Hannon MJ, study authors

¹Results obtained with Dexcom G6 rtCGM system; similar results expected with Dexcom G7 given similar performance and feature sets and better usability. 1 Friel K. Diabetic medicine 2022;39:14653. Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom ONE, Dexcom ONE+, Dexcom Share, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. ©2024 Dexcom International Ltd. All rights reserved. Dexcom International Ltd and its affiliated European entities. This product is covered by U.S. patent. dexcom.com | +1.858.200.0200 Dexcom, Inc. 6340 Sequence Drive San Diego, CA 92121 USA | MDSS GmbH Schiffgraben 41 30175 Hannover, Germany.